Диссертация (1139667), страница 32
Текст из файла (страница 32)
Lancet. 2010;376(9735):112–123.236. O’Gara PT, Kushner FG, Ascheim DD, et al; American College of CardiologyFoundation/American Heart Association Task Force on Practice Guidelines. 2013ACCF/AHA guideline for the management of ST-elevation myocardial infarction: areport of the American College of Cardiology Foundation/American Heart AssociationTask Force on Practice Guidelines. Circulation. 2013;127(4): 362– 425.237.
O'Carroll R, Whittaker J, Hamilton B, Johnston M, Sudlow C, Dennis M (2011)Predictors of adherence to secondary preventive medication in stroke patients. AnnBehav Med 41(3): 383–90.238. Ortega G., Jacas C., Quintana M. et al. Citicoline treatment preventsneurocognitive decline after a first ischemic stroke // Cerebrovasc. Dis. 2010; 29(Suppl2): 268.239. Ostlund U, Persson C (2014) Examining Family Responses to Family SystemsNursing Interventions: An Integrative Review. J Fam Nurs 20(3): 259–286.240. PaolucciS.Epidemiologyandtreatmentofpost-strokedepression.Neuropsychiatr Dis Treat.
2008;4(1):145–154.241. Paradiso S, Vaidya J, Tranel D, Kosier T, Robinson R. Nondysphoric depressionfollowing stroke. J Neuropsychiatry Clin Neurosci. 2008;20(1):52–61.231242. Parnetti L., Mignini F., Tomassoni D. et al. Cholinergic precursorsin thetreatment of cognitive impairment of vascular origin // J.Neurol.Sci, 2007. — V. 257.— P.
264-269.243. Patel B, Lawrence AJ, Chung AW, Rich P, Mackinnon AD, Morris RG, BarrickTR, Markus HS. SourceCerebral microbleeds and cognition in patients withsymptomatic small vessel disease. Stroke. 2013 Feb;44(2):356-61.244. Patel MR, Mahaffey KW, Garg J, et al; ROCKET AF Investigators.Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med.2011;365(10):883–891.245. Pendlebury S.T., Rothwell P.M. Prevalence, incidence and factors associatedwith prestrike and post-stroke dementia: a systematic review and meta-analysis.
LancetNeurol 2009;8(11):1006–18.246. Peng B, Ni J, Anderson CS, Zhu Y, Wang Y, Pu C, et al. (2014) on behalf of theSMART Investigators. (2014) Implementation of a Structured Guideline–BasedProgram for the Secondary Prevention of Ischemic Stroke in China. Stroke 45: 515–519.247. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY.
A novel userfriendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients withatrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–1100.248. Powers WJ, Clarke WR, Grubb RL Jr, Videen TO, Adams HP Jr, Derdeyn CP;COSS Investigators. Extracranial-intracranial bypass surgery for stroke prevention inhemodynamic cerebral ischemia: the Carotid Occlusion Surgery Study randomized trial.JAMA. 2011;306(18):1983–1992.249. Poynter B, Shuman M, Diaz-Granados N, Kapral M, Grace S, Stewart D. Sexdifferences in the prevalence of post-stroke depression: a systematic review.Psychosomatics. 2009;50(6):563–569.250.
Pullicino PM, Qian M, Sacco RL, et al. Recurrent stroke in the warfarin versusaspirin in reduced cardiac ejection fraction (WARCEF) trial. Cerebrovasc Dis.2014;38(3):176–181.232251. Radman N, Staub F, Aboulafia-Brakha T, Berney A, Bogousslavsky J, AnnoniJM. Poststroke fatigue following minor infarcts: a prospective study. Neurology. 2012Oct 2;79(14):1422-7.252. Ray KK, Seshasai SR, Wijesuriya S, et al.
Effect of intensive control of glucoseon cardiovascular outcomes and death in patients with dia¬betes mellitus: a metaanalysis of randomised controlled trials. Lancet. 2009;373(9677):1765–1772.253. Razay G., Vreugdenhil A., Wilcock G. The metabolic syndrome and Alzheimerdisease // Arch. Neurol.
2007; 64(1): 93-96.254. Reddy VY, Holmes D, Doshi SK, Neuzil P, Kar S. Safety of percuta¬neous leftatrial appendage closure: results from the Watchman Left Atrial Appendage System forEmbolic Protection in Patients with AF (PROTECT AF) clinical trial and the ContinuedAccess Registry.
Circulation. 2011;123(4):417–424.255. Review Manager (RevMan) [Computer program]. Version 5.0. Copenhagen:The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.256. Ritter MA, Kochhäuser S, Duning T, et al. Occult atrial fibrillation incryptogenic stroke: detection by 7-day electrocardiogram versus implantable cardiacmonitors. Stroke. 2013;44(5):1449–1452.257. Robinson R, Jorge R, Moser D, et al. Escitalopram and problemsolving therapyfor prevention of poststroke depression: a randomized controlled trial.
JAMA.2008;299(20):2391–2400.258. Röther J, Alberts MJ, Touzé E, Mas JL, Hill MD, Michel P, et al. Risk factorprofile and management of cerebrovascular patients in the REACH Registry.Cerebrovasc Dis. 2008; 25: 366–374.259. Sabia S, Marmot M, Dufouil C, Singh-Manoux A. Smoking history andcognitive function in middle age from the Whitehall II study. N Engl J Med.2008;359:1213-1217.260.
Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y,Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlof B,De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste233M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VandermaelenC, Voigt T, Weber M, Yoon BW. Aspirin and extended-release dipyridamole versusclopidogrel for recurrent stroke. N Engl J Med.
2008;359:1238-1251.261. Sacco RL, Kasner SE, Broderick JP, et al; American Heart Association StrokeCouncil, Council on Cardiovascular Surgery and Anesthesia; Council on CardiovascularRadiology and Intervention; Council on Cardiovascular and Stroke Nursing; et al. Anupdated definition of stroke for the 21st century: a statement for healthcareprofessionals from the American Heart Association/American Stroke Association.Stroke. 2013;44(7):2064–2089.262. Sachdev P.S., Chen X., Joscelyne A.
et al. Hippocampal size and dementia instroke patients: the Sydney stroke study. J Neurol Sci 2007;260(1–2):71–7.263. Sanna T, Diener HC, Passman RS, et al; CRYSTAL AF Investigators.Cryptogenicstrokeandunderlyingatrialfibrillation.NEnglJMed.2014;370(26):2478–2486.264. Sanossian N, Ovbiagele B. Prevention and management of stroke in very elderlypatients. Lancet Neurol. 2009;8(11):1031–1041.265. Savva G.M., Stephan B.C.
Alzheimer’s Society Vascular Dementia SystematicReview Group. Epidemiological studies of the effect of stroke on incident dementia: asystematic review // Stroke. 2010; 41: 41–46.266. Schneider J.A., Aggarwal N.T., Barnes L., Boyle P., Bennett D.A. Theneuropathology of older persons with and without dementia from community versusclinic cohorts // J. Alzheimers. Dis. 2009; 18: 691-701.267. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al.Chapter 12: Interpreting results and drawing conclusions.
In: Higgins JPT, Green S,editors. Cochrane handbook for systematic reviews of interventions. Version 5.1.0[updated March 2011]. The Cochrane Collaboration, 2011.268. Scottish Intercollegiate Guidelines Network (2008) Management of Patientswith Stroke or TIA: Assessment, Investigation, Immediate management and SecondaryPrevention.
Clinical Guideline 108. Accessed 06 December 2014.234269. Serrano S, Domingo J, Rodriguez-Garcia E, Castro MD, del Ser T. Frequency ofcognitive impairment without dementia in patients with stroke: a two-year follow-upstudy. Stroke. 2007;38:105–110.270. Serrano S., Domingo J., Rodriguez-Garcia E.
et al. Frequency of cognitiveimpairment without dementia in patients with stroke: a two-year follow-up study //Stroke. 2007; 38(1): 105-110.271. Sevush-Garcy J, Gutierrez J. An epidemiological perspective on race/ethnicityand stroke. Curr Cardiovasc Risk Rep. 2015;9:19.272. Sharma M, Romas JA . Theoretical foundations of health education and healthpromotion. Sudbury, Jones and Bartlett Publishers. – 2008. - 306.273. Sharpe M, Hawton K, House A, et al.
Mood disorders in long-term survivors ofstroke: associations with brain lesion location and volume. Psychol Med.2009;20(04):815–828.274. Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K,Ohashi Y, Tanahashi N, Yamamoto H, Genka C, Kitagawa Y, Kusuoka H, NishimaruK, Tsushima M, Koretsune Y, Sawada T, Hamada C. Cilostazol for prevention ofsecondary stroke (CSPS 2): An aspirin-controlled, double-blind, randomised noninferiority trial. Lancet Neurol.
2010;9:959-968.275. Shinohara Y, Nishimaru K, Sawada T, Terashi A, Handa S, Hirai S, Hayashi K,Tohgi H, Fukuuchi Y, Uchiyama S, Yamaguchi T, Kobayashi S,Kondo K, Otomo E,Gotoh F. Sarpogrelate-aspirin comparative clinical study for efficacy and safety insecondary prevention of cerebral infarction (S-ACCESS): A randomized, double-blind,aspirin-controlled trial. Stroke. 2008;39:1827-1833.276. Siennicki-Lantz A, Reinprecht F, Wollmer P, Elmstahl S. Smokingrelatedchanges in cerebral perfusion in a population of elderly men. Neuroepidemiology.2008;30:84–92.277. Singer DE, Chang Y, Borowsky LH, et al. A new risk scheme to predictischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA studystroke risk score.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
